Serum PSA decline after Casodex withdrawal.
Schellhammer
P F
PF
Kolvenbag
G J
GJ
D000813:Anilides / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000097:blood*; D014105:Tosyl Compounds
D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen